JPRN-jRCT2080222672未知2 期
A Phase II, multi-center, randomized, double-blind study of T-4288 in patients with community-acquired pneumonia
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 个研究点开始时间: 2014年11月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Age: 20 years of age and older
- •2. Gender : Both
- •3. Confirmed clear infiltrative shadow by chest X-ray or CT within 48 hours prior to the first administration of the study drug
- •4. Confirmed at least one of the following changes in laboratory values;
- •-WBC increased (WBC > 10000 /mm3)
- •-Stab cell > 15%
- •-WBC decreased (WBC < 4500 /mm3)
- •5. Confirmed at least one of the following clinical symptoms and/or findings:
- •-Abnormal findings on auscultation and/or percussion
- •-Dyspnea or tachypnea
- •-Hypoxemia
排除标准
- •1. Having improvement of clinical symptoms due to pneumonia by other systemic antibiotics
- •2. Having a history of allergy to macrolide or quinolone antibiotics
研究者
相似试验
进行中（未招募）
1 期
A study to test how well a new medicine called sirukumab works in patients with Severe Uncontrolled Asthmasubjects with severe, poorly controlled asthmaMedDRA version: 19.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2016-001244-19-ESGlaxoSmithKline, S.A.175
进行中（未招募）
不适用
Dose finding clinical study, multicentre, with allergy vaccines for patients allergic to Phleum pratense pollen at different doses and placebo, a substance with inactive ingredients of medicine and whose appearance is identical to that of the actual treatment in question.EUCTR2011-000814-21-PTBIAL INDUSTRIAL FARMACEUTICA, S.A.150
进行中（未招募）
不适用
Dose finding clinical study, multicentre, with allergy vaccines for patients allergic to Phleum pratense pollen at different doses and placebo, a substance with inactive ingredients of medicine and whose appearance is identical to that of the actual treatment in question.allergic rhinoconjunctivitis induced by grass pollenMedDRA version: 14.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 10015919 - Eye disordersEUCTR2011-000814-21-ESBIAL INDUSTRIAL FARMACEUTICA, S.A.150
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE)EUCTR2016-000488-17-FRILTOO PHARMA100
进行中（未招募）
1 期
A study to evaluate the effectiveness and safety of the study drug, when patients are given dosage of ILT-101 with active moderate to severe systemic lupus erythematosus(SLE)EUCTR2016-000488-17-PTILTOO PHARMA100